Document Detail


Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure.
MedLine Citation:
PMID:  25146697     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Nanotechnology has impacted tremendously the medical research with increasing importance in the development of new therapeutic approaches and applications. Among these applications, the use of nanocarriers have gained particular interest in order to achieve successful delivery of therapeutics and imaging agents for the treatment and diagnostics of different diseases, such cancer, infections, diabetes and lung, brain and cardiovascular diseases. Heart failure (HF) is a complex clinical syndrome derived from multiple causes that arise from secondary to inherited or acquired abnormalities of cardiac structure and/or function. Myocardial infarction (MI), the major cause of HF, continues to be an increasing problem in terms of morbidity, mortality and healthcare costs worldwide. Currently, established pharmacologic drugs have proven to be effective in reducing hypertrophy, remodeling of the myocardium, and reduce morbidity and mortality in patients with HF. However, despite optimal treatment with existing drugs, the prognosis of HF is poor, and also the possible deleterious effects of therapeutic agents must be considered when used at doses required for the desired therapeutic effect. Therefore, novel therapeutic strategies are urgently needed to prevent high morbidity and mortality associated with MI and HF. In this review, we will present recent developments in nanomedicine research envisaged to have an important impact on the treatment of cardiovascular diseases, particularly MI. In addition, we will discuss the use of different advanced modified nanosystems for molecular imaging and therapeutics of MI, presenting several in vitro and in vivo examples. Finally, we will conclude with an overview of the potential of nanomedicines in the future for the treatment of cardiovascular diseases.
Authors:
Mónica P A Ferreira; Vimalkumar Balasubramanian; Jouni Hirvonen; Heikki Ruskoaho; Helder A Santos
Related Documents :
25146697 - Advanced nanomedicines for the treatment and diagnosis of myocardial infarction and hea...
22182477 - Acute myocardial infarction in a patient with hypofibrinogenemia: a case report.
12846547 - Unexpected accumulation of thallium-201 in bilateral thalamic venous infarction induced...
25352827 - Collaterals: an important determinant of prolonged ischemic penumbra versus rapid cereb...
23679267 - Clinical and histopathological analysis of 66 cases with cardiac myxoma.
21411147 - Fulminant myocarditis associated with novel h1n1 influenza a.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-21
Journal Detail:
Title:  Current drug targets     Volume:  -     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of KIBRA rs17070145 polymorphism with episodic memory in the early stages of a human neu...
Next Document:  Management of Inflammatory Bowel Disease Patients with a Cancer History.